2016 · Journal of pharmaceutical and biomedical analysis · paywalled
Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology
Rood et al.
The finding, in our words
The review maps expanding bioanalytical validation of kinase inhibitor quantitation from dried blood spots and other matrices, with tandem mass spectrometry reaching low picogram per millilitre limits, which advances decentralised therapeutic drug monitoring in oncology.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
A review of 39 studies found that dried blood spot and volumetric absorptive microsampling show promising results for therapeutic drug monitoring of oral targeted anticancer drugs. The authors state that external validation remains crucial to confirm reliability, citing haematocrit effects and sample stability as key challenges.
Meertens et al., Biomedical Chromatography · source ↗
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
The authors observe that self-sampling devices for capillary blood are gaining traction as a patient-preferred alternative to venous collection, with one centre reporting a 15 percent reduction in laboratory test volumes when local collection was offered. They argue that successful integration into total laboratory automation requires addressing cost, transport regulations and sample volume adequacy while ensuring robust device design and seamless workflow compatibility.
Poland & Cobbaert, Clinical chemistry and laboratory medicine (paywalled) · source ↗
LC-MS/MS measurement of imatinib and its active metabolite from volumetric dried blood spots collected via HemaXis DB10 and Capitainer B demonstrated analytical precision across hematocrits from 22% to 55% alongside 43-day ambient stability. Clinical evaluation across 52 paired samples showed high agreement with plasma concentrations, verifying both devices as reliable options for decentralised therapeutic drug monitoring.
Orleni et al., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (paywalled) · source ↗